Next Day Disclosure Return

COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE

Boyouping®, China’s First Locally Developed Dulaglutide Injection, Approved for Marketing

Yantai, August 8, 2025 –- Boan Biotech announced that China’s National Medical Products Administration (NMPA) has granted marketing approval to its Boyouping® (Dulaglutide Injection), indi...

VOLUNTARY ANNOUNCEMENT DULAGLUTIDE INJECTION (BOYOUPING) APPROVED FOR MARKETING IN CHINA

PLACING OF NEW SHARES UNDER GENERAL MANDATE

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2025

Dr. Changlin Dou Appointed IFPMA ICH M18 Task Force Lead Expert

Recently, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), as a standing observer of the International Council for Harmonisation of Technical Requirements for P...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2025

Articles of Association

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION